WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

Strona główna・Stock List・Dynex Capital Inc

Dynex Capital Inc

Closed

SectorReal estate

12.41 0.08

Buy Sell

Overview

Share price change

24h

Current

Min

12.24

Max

12.55

Key metrics
By Trading Economics
Income	35M 185M
Sales	38M 177M
P/E Sector Avg	5.29 67.236
EPS	0.22
Dividend yield	15.31
Profit margin	104.701
Employees	28
EBITDA	169M 319M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+23.08% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	15.31% 6.64%
Next Earnings	20 kwi 2026

Market Stats
By TradingEconomics
Market Cap	499M 2.7B
Previous open	12.33
Previous close	12.41

News Sentiment

By Acuity

50%

61 / 167 Ranking in Real estate

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

10.785 / 11.125 Support & Resistance

Dynex Capital Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 mar 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mar 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar 2026, 22:42 UTC

Market Talk

Major News Events

Global Equities Roundup: Market Talk

23 mar 2026, 22:42 UTC

Market Talk

Major News Events

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar 2026, 22:18 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mar 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar 2026, 21:10 UTC

Major News Events

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mar 2026, 20:50 UTC

Market Talk

Earnings

Major News Events

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Dynex Capital Inc Forecast

Price Target

By TipRanks

23.08% upside

12 Months Forecast

Average 15.25 USD 23.08%

High 15.25 USD

Low 15.25 USD

Based on 1 Wall Street analysts offering 12 month price targets forDynex Capital Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Dynex Capital Inc - Dist in the past 3 months.

Technical Score

By Trading Central

10.785 / 11.125Support & Resistance

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

61 / 167 Ranking in Real estate

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Dynex Capital Inc

Dynex Capital, Inc., a mortgage real estate investment trust, invests in mortgage-backed securities (MBS) on a leveraged basis in the United States. It invests in agency and non-agency MBS consisting of residential MBS, commercial MBS (CMBS), and CMBS interest-only securities. Agency MBS have a guaranty of principal payment by an agency of the U.S. government or a U.S. government-sponsored entity, such as Fannie Mae and Freddie Mac. Non-Agency MBS have no such guaranty of payment. The company has qualified as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal income taxes if it distributes at least 90% of its taxable income to its stockholders as dividends. Dynex Capital, Inc. was incorporated in 1987 and is headquartered in Glen Allen, Virginia.